Wednesday, July 8, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Clinical program

Immune Globulin Intravenous (human), 10%

Phase 3 · mab · Multifocal Motor Neuropathy

Immune Globulin Intravenous (human), 10% for Multifocal Motor Neuropathy is a Phase 3 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).

← All Takeda projects Phase 3 mab completed

Internal code 160604

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Phase 3
Modality
mab
Indication
Multifocal Motor Neuropathy
Status
completed
Trials
1